Relaxin-3/RXFP3 networks: an emerging target for the treatment of depression and other neuro psychiatric diseases?

Craig M Smith; Andrew W Walker; Ihaia T Hosken; Berenice E Chua; Cary Zhang; Mouna Haidar; Andrew L Gundlach

Journal article

Relaxin-3/RXFP3 networks: an emerging target for the treatment of depression and other neuro psychiatric diseases?

Craig M Smith, Andrew W Walker, Ihaia T Hosken, Berenice E Chua, Cary Zhang, Mouna Haidar, Andrew L Gundlach

FRONTIERS IN PHARMACOLOGY | FRONTIERS MEDIA SA | Published : 2014

DOI: 10.3389/fphar.2014.00046

Download PDF

Abstract

Animal and clinical studies of gene-environment interactions have helped elucidate the mechanisms involved in the pathophysiology of several mental illnesses including anxiety, depression, and schizophrenia; and have led to the discovery of improved treatments. The study of neuropeptides and their receptors is a parallel frontier of neuropsychopharmacology research and has revealed the involvement of several peptide systems in mental illnesses and identified novel targets for their treatment. Relaxin-3 is a newly discovered neuropeptide that binds, and activates the G-protein coupled receptor, RXFP3. Existing anatomical and functional evidence suggests relaxin-3 is an arousal transmitter whi..

View full abstract

University of Melbourne Researchers

Andrew Gundlach Author Anatomy and Physiology

Related Projects (3)

Peptide neurotransmission in mental health and psychiatric illness

Our laboratory recently discovered the brain 'transmitter' called 'relaxin-3', and are researching how it affects brain activity and animal ..

Modulatory control of arousal and affect in health and disease

Mental illness is a significant social and economic burden worldwide and knowledge of the underlying causes and more effective therapies are..

Neural networks and transmitters controlling behavioural state and cognition

Mental illness and dementia are significant social and economic burdens worldwide and knowledge of their underlying causes and more effectiv..

Grants

Awarded by National Health and Medical Research Council (NHMRC) of Australia

Funding Acknowledgements

The research in the authors' laboratory reviewed here was supported by grants from the National Health and Medical Research Council (NHMRC) of Australia (509246, 1005988, and 1024885) and the Pratt and Besen Foundations, and by the Victorian Government Strategic Investment. Andrew L. Gundlach is an NHMRC (Australia) Senior Research Fellow and a Brain & Behavior Research Foundation (USA) NARSAD Independent Investigator. The authors acknowledge the contribution of their current and former colleagues to the relaxin-3 related research reviewed.